Stocks To Buy Now

Blog


121 Mining Investment is in Las Vegas To Offer Two Days of Investment Meetings and Exceptional Market Analysis

121 Mining Investment Las Vegas (28-29 March) offers junior resource companies and investors from the mining spectrum a unique platform to connect and network for future growth and key business prospects.

The CEOs from 55 vetted natural resource companies are heading to bustling Las Vegas to present project updates and meet over 150 investors for two days of 1-2-1 meetings.

These meetings will run alongside a content-packed conference schedule, covering topics such as the energy transition, the gold outlook, precious metals investment strategies, uranium, and the impacts of megatrends on metals and mining investing.

Qualified investors are able to attend the event free of charge. Attending investors will not only be able to schedule 1-on-1 meetings with leading mining company CEOs and hear analysts and stock pickers present, they will also be able to enjoy the fantastic networking Las Vegas has to offer. All attendees are also invited to 121 Las Vegas networking drinks at Circa’s Legacy Club rooftop bar on March 28th from 17:00.

If you are unfamiliar with 121 Group, they are the world’s leading dedicated mining investment event series, organising summits worldwide. Their portfolio includes events in London, New York, Cape Town, Hong Kong, Sydney, Melbourne, Singapore and Las Vegas.

Whether you are an investor looking for exciting new projects, or a mining company hoping to raise capital and make new connections, 121 Mining Investment Las Vegas is THE premier forum to make it happen.

To learn more, please visit https://ibn.fm/KAfYA

From Our Blog

Nutriband Inc. (NASDAQ: NTRB) Innovating Abuse-Deterrent Drug Delivery in a Shifting Opioid Landscape

May 9, 2025

A Market Demanding Safer Opioid Solutions The opioid crisis remains a critical public health challenge in the U.S. and globally, prompting a series of new regulatory measures designed to improve safety and reduce misuse. In early 2025, the FDA approved Journavx (suzetrigine), a first-in-class non-opioid painkiller offering patients safer alternatives to opioids. Additionally, opioid manufacturers […]

Rotate your device 90° to view site.